Organelle-targeted BODIPY-conjugated platinum( iv ) anticancer prodrugs for overcoming drug resistance
Dalton Transactions · 2025
DOI: 10.1039/d4dt03249g ↗Kurz gefasst
Fachartikel in der Zeitschrift Dalton Transactions, 2025. Verfasst von Yuelun Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Flow Chemistry and Engineering, School of Chemistry and Materials, Jiangxi Normal University, Nanchang 330022, China. tyuan@jxnu.edu.cn. Hauptthemen laut MEDLINE: Prodrugs, Boron Compounds, Antineoplastic Agents, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province.
Abstract (Originalsprache)
A novel platform combining light-triggered activation and organelle-targeted platinum( iv ) prodrugs was developed to overcome chemotherapy resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Flow Chemistry and Engineering, School of Chemistry and Materials, Jiangxi Normal University, Nanchang 330022, China. tyuan@jxnu.edu.cn.
- Jiangxi Province Key Laboratory of Natural and Biomimetic Drugs Research, School of Health, Jiangxi Normal University, Nanchang 330022, China.
ORCID-Profile: Houzong Yao
Förderung
- Natural Science Foundation of Jiangxi Province
Zitieren
APA
Xu, Y., Zhang, F., Li, M., Zhang, H., Yuan, Y., Lin, S., Yao, L., Xu, S., Yuan, T., & Yao, H. (2025). Organelle-targeted BODIPY-conjugated platinum( iv ) anticancer prodrugs for overcoming drug resistance. Dalton Transactions. https://doi.org/10.1039/d4dt03249g
Vancouver
Xu Y, Zhang F, Li M, Zhang H, Yuan Y, Lin S, et al. Organelle-targeted BODIPY-conjugated platinum( iv ) anticancer prodrugs for overcoming drug resistance. Dalton Transactions. 2025. doi:10.1039/d4dt03249g
BibTeX
@article{Xu2025,
author = {Xu, Yuelun and Zhang, Fengling and Li, Miaomiao and Zhang, Huimin and Yuan, Yuhong and Lin, Siying and Yao, Liuxuan and Xu, Shunfang and Yuan, Tao and Yao, Houzong},
title = {Organelle-targeted BODIPY-conjugated platinum( iv ) anticancer prodrugs for overcoming drug resistance},
journal = {Dalton Transactions},
year = {2025},
doi = {10.1039/d4dt03249g}
}
EUVIMED